Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Update

Akari Therapeutics, Plc (NASDAQ:AKTX) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 74,100 shares, a growth of 30.2% from the November 30th total of 56,900 shares. Approximately 0.6% of the shares of the company are sold short. Based on an average daily volume of 44,100 shares, the short-interest ratio is currently 1.7 days.

Akari Therapeutics Stock Down 1.2 %

AKTX traded down $0.01 during trading on Friday, hitting $0.97. The company’s stock had a trading volume of 95,614 shares, compared to its average volume of 25,109. The business’s 50 day simple moving average is $1.63 and its 200-day simple moving average is $2.73. Akari Therapeutics has a one year low of $0.90 and a one year high of $4.40.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Akari Therapeutics in a research report on Saturday. They set a “sell” rating for the company.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.